Screener
Halozyme Therapeutics HALO Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accrued outsourced manufacturing expenses | 5,181 | 11,775 |
| Taxes payable | 26,426 | 44,148 |
| Product returns and sales allowance | 44,108 | 46,594 |
| Other accrued expenses | 86,264 | 104,349 |
| Lease liability | 31,879 | 34,569 |
| Total accrued expenses | 214,542 | 270,056 |
| Less long-term portion | (102,681) | (113,863) |
| Total accrued expenses, current | $111,861 | $156,193 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's operating lease liabilities (current)?
- Halozyme Therapeutics (HALO) reported operating lease liabilities (current) of $31.88M in Q2 2026.
- How has Halozyme Therapeutics's operating lease liabilities (current) changed year-over-year?
- Halozyme Therapeutics's operating lease liabilities (current) increased by 10.0% year-over-year, from $28.97M to $31.88M.
- What is the long-term trend for Halozyme Therapeutics's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's operating lease liabilities (current) has grown at a 48.0% compound annual growth rate (CAGR), from $4.87M to $34.57M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about Halozyme Therapeutics's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude